The increasing importance of targeting drugs in the treatment of several tumor entities (breast, colon, lung, malignant melanoma (MM), lymphoma, and so on) and the necessity of a companion diagnostic (human epidermal growth factor receptor 2, Kirsten rat sarcoma viral oncogene, epidermal growth factor receptor (EGFR), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), and so on) is leading to new challenges for surgical pathology. As all the biomarkers to be specifically detected are tissue based, a precise and reliable diagnostic is absolutely crucial. To meet this challenge, surgical pathology has adapted a number of molecular methods (semi-quantitative immunohistochemistry, fluorescence in situ hybridization), PCR and its multiple variants, (pyro/Sanger) sequencing, next-generation sequencing, DNA-arrays, methylation analyses, and so on) to be applicable for formalin-fixed paraffinembedded (FFPE) tissue. To read a patients' tissue as 'deeply' as possible and to obtain information on morphological, genetic, proteomic as well as epigenetic background is the actual task of pathologists and molecular biologists in order to provide the clinicians with information relevant for individualized medicine. The intensified cooperation of clinicians and pathologists will provide the basis of improved clinical drug selection as well as guide development of new cancer gene therapies and molecularly targeted drugs by research units and the pharmaceutical industry. This review will give some information on (1) biomarker detection methods adapted to FFPE tissue, (2) the potency of predictive pathology in tumor detection and treatment and (3) the implications of pathology on the development of new drugs in molecularly targeted and gene therapies.
INTRODUCTION
The implementation of personalized medicine has revolutionized the current strategies in oncology. A key issue of the new treatment procedures is the fact that several so called targeted drugs may only be efficacious when tumors exhibit characteristic molecular features, for example, the therapeutic antibody Cetuximab (Erbitux)) is active against colon cancer only when the tumor is Kirsten rat sarcoma viral oncogene (KRAS) wild type or Gefitinib (Iressa), a small molecule epidermal growth factor receptor (EGFR) kinase inhibitor, appears to inhibit cell growth only when the tumor cells have an activating EGFR mutation. Other examples are shown in Table 1 . This situation leads to the consequence that before treatment an eligibility test has to be performed. 1 As almost all pre-therapeutic tests are tissue based, surgical pathology is facing both a new chance and a challenge creating the new field of predictive molecular pathology. This changing 'molecular world' has already notable impact on 'classical' pathology.
According to the World Health Organization (WHO) Blue Series and textbooks of pathology malignant tumors are classified on the basis of histogenesis, histological type, differentiation and other morphological and immunohistochemical characteristics. However, tumors of the same group are molecular heterogeneous encompassing different lesions with distinct biological features. As classical histopathology is only partly able to mirror and predict clinical behavior of individual tumors new molecular tests and methods will have to be added into the morphology-based diagnostic procedure to read a patient's tissue as 'deeply' as possible and to obtain combined information on morphological, genetic, proteomic as well as on epigenetic alterations. This has become the upcoming task of surgical pathology. The aims are:
1. to provide clinicians with predictive information on the behavior of individual malignant tumors, for example, drug response, prognosis and the potential to metastasize; 2. to unravel defined characteristics of a given tumor (overexpression of proteins, genetic alterations, and so on) relevant for clinical drug selection regarding the individual patient; 3. to stimulate future biomarker research on human tissue that will define the basis for the development of new targeted drugs by research units and pharmaceutical industry.
Despite this highly fascinating outlook it has to be emphasized that for the foreseeable future WHO-based surgical pathology will have the dominant role in daily diagnostic and patient management. The human tissue sample will remain the gold standard resource for all upcoming new diagnostic techniques, which first of all has to be precisely characterized by conventional histomorphology. The consecutive new molecular analysis-based tissue interpretation will provide 'add-on information' and should become a part of the diagnostic process hopefully adding those data that conventional morphology is not able to contribute.
On this common ground the process of diagnostic and the treatment of cancer will be optimized.
This review considers state-of-the-art of molecular pathology for guiding targeted cancer treatment. As many cancer gene therapies involve strategies that target specific molecular abnormalities, the field of molecular pathology may be particularly relevant for the development and clinical application of this treatment modality.
METHODOLOCIGAL CONSIDERATIONS
During the last decade, surgical pathology has adapted several molecular methods to formalin-fixed paraffin-embedded (FFPE) tissue (Table 2) to solve many scientific and diagnostic challenges. This approach is capable of both identifying novel genes associated with disease development and also defining clusters of genes predicting clinical outcome. Without providing details it must be emphasized that carefully controlled preanalytic procedures and standard operating procedures as well as sufficient bio-mathematic knowledge are a crucial prerequisite to meet the challenges of reliable and reproducible results.
New molecular methods adapted to FFPE tissue FFPE is still the most widely used method for tissue preparation in the routine diagnostic setting. It is easy-to-use, cost-effective and does not require special expertise, costly infrastructure or costly equipment. It can be done in developed as well as in developing countries. However, extracting nucleic acids or proteins for molecular analysis from FFPE tissue has been cumbersome in the past and previously has limited the use of molecular methods. To overcome this problem, in the last years a multitude of reliable protocols for DNA, RNA and protein extraction from FFPE tissue have been developed and the use of neutral buffered formalin for 24-48 h can be regarded as standard procedure. [2] [3] [4] [5] A detailed description with many practical information is given by Stanta et al. 6 This includes conventional extraction protocols, which have to be carried out by hand as well as semi-automated and fully automated extraction systems 2 (for example, Siemens VERSANT kPCR Molecular System, Erlangen, Germany). Today, if the tissue is timely preserved in 10% buffered formaldehyde (final concentration: 4%) and if standard paraffin-embedding procedures are used, DNA and RNA of sufficient quality for molecular diagnostics can easily be obtained. [7] [8] [9] [10] Snap-frozen tissue on the other hand, may be better suited for the extraction of DNA, RNA as well as proteins, however, such tissue can only be obtained in the setting of large hospitals with a specific infrastructure and specially trained personnel. Therefore, the use of diagnostic assays based on frozen tissue is and will remain limited.
Quality control
As the molecular analyses are relatively complex methods, these techniques should only be performed in laboratories, which have proved the capability on a reliable and reproducible level. This is best performed by round robin tests, which should be organized by an independent organization. In Germany the Deutsche Gesellschaft fü r Pathologie (DGP) since years performs a quality control initiative, called QuiP (Quality in Pathology) to periodically perform ring trials, for example, on estrogen receptor, progesterone receptor, hepidermal growth factor receptor 2 (HER2), KRAS, EGFR, BRAF, stem cell factor receptor/CD117, B-and T-cell clonality, and so on, (details see http://www.dgp-berlin.de). Only institutes of pathology, which have passed the trial will receive a certificate and are recommended as qualified for the tests.
In Europe, other QC activities are also available, such as the Nordic Immunohistochemical Quality Control (NordiQC), the European EQA program for testing biomarker mutations established by the European Society of Pathology and a QA Program of the Faculty of Pathology, RCPI in the United Kingdom, United Kingdom National External Quality Assessment Service (UK-NEQAS).
Pre-analytic selection of tumor tissue Biopsy materials often consist of only 10 to 20% tumor cells. Normally this is absolute sufficient to allow a correct histopathological diagnosis. However, for a molecular analysis a procedure called 'tumor cell enrichment' should be conducted before the molecular assay. This means that the tumor containing parts of the tissue must first be identified by a pathologist under the microscope and second specifically be prepared from the paraffin block by so called 'manual microdissection' 11 reliably producing a tumor cell count of 420-30%. 9 Typical examples are shown in Figure 1 . Only then a reliable and reproducible DNA/RNA Gefitinib-non-small cell lung cancer with mutated EGFR Erlotinib-non-small cell lung cancer with mutated EGFR Crizotinib-non-small cell lung cancer with mutated EML4-ALK Nimotuzumab-metastatic colorectal cancer (still experimental) Lapatinib-metastatic breast cancer overexpression HER2/neu (?) Vemurafenib (PX4032)-malignant melanoma with mutated B-RAF Imatinib-CML, bcr/abl-positive (activated PK) Imatinib-GIST with activated c-kit receptor tyrosine kinase/ CD117, exon 9 mut Rituximab ( þ CHOP), Y90-Ibritumomab, I131-TositumomabNHLymphoma with CD20 Gemtuzumab-Ozogamicin-AML with CD33 (460 years), mal. melanoma Tamoxifen þ / À chemo-ER þ /HER2-breast cancer, mutation pattern-multigene assays (for example, EndoPredict) Abbreviations: ALK, anaplastic lymphoma kinase; AML, acute myeloid leukemia; CHOP, cyclophosphamide, doxorubin, vincristine, and prednisone; CML, chronic myeloid leukemia; EGFR, epidermal growth factor receptor; EMA, epidermal membrane antigen; EML4, echinoderm microtubule-associated protein like 4; ER, estrogen receptor; FDA, Food and Drug Administration; HER2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma viral oncogene. Abbreviations: CISH, chromogen in situ hybridization; ELISA, enzyme-linked immunosorbent assay; FISH, fluorescence in situ hybridization; LOH, loss of heterogeneity extraction followed mutation testing is possible, otherwise one has to state 'garbage in, garbage out'.
Tissue preparation for PCR-based molecular assays Besides tissue selection also tissue preparation is crucial for a valid result on which treatment can be based. Some basics are listed in the following: Molecular analyses can be performed on tissue specimens, cytological cell blocks and cytological smears. If formalin-fixed tissue is used, it is important to comply with standard conditions for fixation as use of unbuffered formalin or extended fixation times can lead to extensive cross-linking and fragmentation of DNA and which is often an obstacle for molecular analyses. It is important to realize that correct molecular results depend on the amount and percentage of tumor cells used for extraction of nucleic acids. A tumor cell content of at least 20-30% is strongly recommended (see above). PCR-based techniques can be applied to previously hematoxylin and eosin, May-Grü nwald-Giemsa and immunostained specimens, as hematoxylin and eosin, May-Grü nwald-Giemsa, Pap and immunocytochemistry do not compromise DNA quality. For DNA/RNA extraction, standardized methods as offered by several vendors are recommended. Even automated systems are available contributing a lot to receive consistently highquality nucleic acids from FFPE tissue.
To further improve the quality of molecular assays, standard operating procedures are recommended for the preanalytic workflow, that is, the way of the resected tissue from the operating theater to the cooperating institute of pathology. More attention on temperature, fixation time, size of the specimens, penetration of the fixative, and so on, appears to be necessary (for details, see Stanta 6 ).
MOLECULAR DIAGNOSTICS OF TUMORS (MOLECULAR CLASSIFICATION)
In diagnostic analyses of solid and hematological tumors, standards and challenges of pathology reports are continuously increasing. To provide the clinician with a solid basis for the choice of treatment, the diagnoses should state a clear decision on tumor type, WHO-code, pathological tumor node metastasis status, dignity, that is, benign, malignant, in situ carcinoma or borderline lesion; histogenesis and prognostic data, as far as available. 12 Nonetheless, there exist different tumor types with very similar histological appearance but different clinical behavior. Further, the same entity can appear with greatly varying morphology. Immunohistochemistry has proven as powerful tool to overcome this problem. To obtain diagnoses as correct and informative as possible, genetic approaches can be helpful in addition to conventional histology. Some examples are given below.
Epithelial tumors
In carcinomatous lesions, molecular methods are of special value, for example, if hereditary tumors are suspected (Table 1) , for example, breast cancer with BRCA-1/2 mutations or colon cancer with alterations in the APC gene indicative for familiar adenomatous polyposis or hereditary non-polyposis colorectal cancer (CRC). Assuming this, methods are available (Table 2) to precisely detect the genetic alterations using routinely FFPE samples. This may open a diagnostic tool for a more precise evaluation of pre-cancerous lesions. Breast cancer HER2, also called HER2/neu, is one of the routinely tested biomarkers in invasive breast cancer. HER2, a member of the EGFR family is a receptor tyrosine kinase, which is overexpressed in about 15% of breast cancers. It is involved in cell growth regulation and differentiation signaling pathways. An amplification of the encoding gene, which is called ERBB2 is correlated with a protein overexpression. The ERBB2 gene is located on the long arm of human chromosome 17 (17q12). In untreated patients, studies have shown an association between an ERBB2 amplification and worse overall survival (OS) compared with non-amplified breast cancers without ERBB2 amplification. 13 The detection of HER2 overexpression can be performed either by immunohistochemistry or by in situ hybridization. The most important primary technique for routine determination of HER2 status is immunohistochemistry, evaluating the membranous expression is analyzed according to the DAKO score respectively the ASCO/cap guidelines. 14 At the DNA-level, several in situ hybridization methods like fluorescence (FISH), chromogen (CISH) or Silver in situ hybridization are available. 15 In addition to the monoclonal antibody trastuzumab, newer therapeutic options such as lapatinib, pertuzumab and trastuzumabemtansin are currently under evaluation in clinical studies. 16 Colon cancer One of the most prominent examples of routine molecular testing for the prediction of therapy success is exemplified by metastasized CRC. It has been known for long that KRAS mutations are frequent events in CRC and mutations at codons 12/13 of exon 2 of the gene lead to hyperactivation of the respective protein.
However, only recently it has been finally proven in clinical trials that hyperactivation of KRAS might completely abolish the effects of an upstream inhibition of the EGFR ( Figure 2 ) by therapeutic antibodies like cetuximab and Panitumumab. 17, 18 It is only since then that KRAS mutation analysis is mandatory before therapy of colorectal carcinoma with these substances. 19 Another application of molecular pathology in CRC refers to the principal genetic mechanisms causing the disease. Different molecular pathways underlie the pathogenesis of CRCs and are associated with heterogeneous biological behaviors. This has been extensively demonstrated for cancers following the microsatellite instability high pathway (MSI-H). MSI-H is a hallmark alteration of Lynch syndrome-associated tumors and is also found in 10 to 15% of sporadic colon cancers. [20] [21] [22] The presence of MSI-H is predictive of a favorable outcome in both, hereditary and sporadic cases. 23, 24 To date, knowledge of the MSI-status is required to address two routine applications/requirements:
1. Following the revised Bethesda guidelines, 25 colon cancer is tested for MSI in order to evaluate the presence of Lynch syndrome and guide further genetic counseling. 2. Moreover, the MSI-status is determined in stage II CRCs when the tumor grading becomes relevant for chemotherapy decision making. Only in the absence of MSI-H, poor differentiation (G3-4) is considered a marker for high risk of systemic recurrence and in favor of adjuvant chemotherapy. 26 Non-small-cell lung cancer (NSCLC) NSCLC mainly subdivided into adenocarcinoma, squamous cell carcinoma, as well as those of type large cell and not other specified, may harbor multiple genetic alterations (for example, KRAS, EGFR, anaplastic lymphoma kinase (ALK), BRAF, c-ros oncogene 1, HER2, fibroblast growth factor receptor 1) whose adequate testing is (EGFR, ALK) and might become (c-ros oncogene-1) a prerequisite for the induction of targeted therapy. 27, 28 The actual standard in most laboratories includes
particularly KRAS (PCR), EGFR (PCR, immunohistochemistry) and ALK-testing (FISH, immunohistochemistry):
KRAS mutations. KRAS mutation is the most frequently (20-35%) mutated oncogene (chromosome 12, primarily codons 12 and 13) in NSCLC. 28, 29 However, detected in the 80s 30 so far clinical value is limited according to the lack of approved therapies. The latter are still under investigation 31 and recent data could show slightly promising effects in KRAS mutant advanced NSCLCs treated with Selumetinib plus Docetaxel. 32 KRAS mutation seems to be a negative prognostic marker of survival (however, discussed somewhat controversy 28, 33 and might be used as 'up-front' testing as almost all KRAS-mutated cases show no EGFR or ALK alterations). 28, 29 However, the latter point might be due to the lack of reimbursement of test costs in some countries. This kind of prescreening is not recommended at the moment (in our institute for example molecular testing of EGFR and ALK is performed in KRAS wild-type as well).
Activating EGFR mutations. Mutations of the EGFR are found in about 15% of NSCLC, with a remarkable ethnic variation between 6% (non-Asian) and 33% (East Asian). 34 The most common activating somatic EGFR mutation types (chromosome 7) are exon 19 microdeletions, which remove a leucine-arginine-glutamic acid-alanine motif and the exon 21 L858R point mutation, which produces a leucine-to-arginine substitution. [35] [36] [37] Further studies (and own unpublished preliminary results) even show exon 18 alterations. 35, 38 Thus, the recommendation for predictive tests is to routinely examine exon 18, 19 and 21. These mutations are crucial for the activity of EGFR-tyrosine kinase inhibitors such as gefitinib (IRESSA) and erlotinib (Tarceva) showing efficacy in the treatment of advanced NSCLC with response rate of approximately 70%. 39 EGFR mutations seem more common in Asians, females, neversmokers and adenocarcinoma histology. 40 Never the less if only the latter were tested one would miss up to one-third of the patients harboring these mutations. Thus, gender, ethnicity and smoking status are not a strict selection criterion for molecular testing and therapy induction. 40 Figure 2. Kirsten rat sarcoma viral oncogene (KRAS)-mitogenactivated protein kinase (MAPK) signaling pathway is inhibited by anti-epidermal growth factor receptor (EGFR) therapeutic antibodies in case of KRAS wild type. Mutated KRAS acts independent of the receptor and stimulates constitutively the pathway and by this proliferation, angiogenesis and invasive growth. Consequently, the KRAS status must be detected before therapy.
ALK rearrangements. Chromosomal alterations might also result in overexpression of fusion proteins targetable by small molecules. One recent example and fast evolving story gaining widespread interest is that of the EML-4-ALK inversion on chromosome 2, detectable in a small subset of about 4% (0.9-13%) [41] [42] [43] [44] [45] of NSCLC: a small paracentric inversion within the short arm might lead to an open reading frame linking the first exons of echinoderm microtubule-associated protein like 4 (EML4) to the 3 0 part of ALK (from exon 20). Other fusion partners (than EML-4) of ALK have been described, 43, 46 characterizing this new molecular subgroup 47 of NSCLC (ALK-rearranged). Encouraging data from a phase I study showed that tumors that harbor such alterations respond exceptionally well to PF-02341066 (Crizotinib), a drugtargeting ALK and MET hepatocyte growth factor receptor, led to the introduction of a phase III trial with this inhibitor in EML4-ALKpositive NSCLCs. 44, 48 In October 2012, therapy with this small molecule (XALKORI) received approval in Europe for ALK-activated (rearranged) NSCLCs, which consist almost exclusively of adenocarcinomas without mutation of EGFR or KRAS, and preferentially arises in non-smokers. 43, 49 Considering this it seems the same as in EGFR-testing, as ALK-rearrangements had also been reported in squamous cell carcinomas (o1%), in smokers and in patients with EGFR mutation. 50 However, the EML4 breakpoint is variable making a PCR-based detection of the fusion transcript difficult. As this rearrangement is usually based on an inversion of EML4 on the same chromosome, this further complicates the use of standard FISH break-apart probes for ALK (Figure 3 -main test in the studies that led to approval) because of technical as well as interpretation difficulties the optimal method of detection (combination?) of this specific genetic alteration still has to be established (in contrast to the anaplastic large cell lymphoma (ALCL), see below).
Thus, KRAS, EGFR and ALK are currently the main targets concerning diagnosis and/or therapy in NSCLC. As combinations of these mutations are possible, 50 however rare, an 'up-front' testing is not recommended at the moment. As the number of new targetable driver mutations might increase within the next years (for example, c-ros oncogene 1) and diagnosis is performed on biopsy specimen in around 80% of the cases (means small amount of testable tumor tissue) the implementation of strategic algorithms developed by clinicians and pathologists is one of the most challenging tasks in the nearer future.
Malignant melanoma BRAF mutations. MMs arise from melanocytes (the pigmentproducing cells) and are located in different body compartments. According to the site of origin, MM can be classified into cutaneous, mucosal, uveal and leptomeningeal melanoma. Depending on these different localizations different etiological factors, clinical behavior and diverse molecular genetic profiles are described. 51 BRAF mutations are most common in cutaneous melanoma. Approximately 50% of metastatic MMs are characterized by mutations of the BRAF oncogene, which leads to a continuously activated kinase with an 800-fold increased activity when compared with the wildtype. 52, 53 RAF proteins are a family of kinases, which are responsible for transmitting extracellular signals from growth factor receptors in the RAS-RAF pathway controlling cell growth, proliferation and differentiation. Mutations in the BRAF gene lead to a constitutive activation of this pathway. The consequence is uncontrolled cell proliferation. The activated kinase is druggable by BRAF inhibitors, which often leads to a dramatic shrinkage of the tumor mass. Whereas OS for metastatic melanoma is consistently 6-8 months in chemotherapy clinical trials, the median OS after therapy with Vemurafenib is up to 13.8 months.
A treatment with the approved BRAF inhibitor Vemurafenib (Zelboraf) requires a valid and reliable molecular mutation diagnostics. Notably, a misdiagnosis of a BRAF mutation may even result in paradoxically accelerated tumor growth.
Until now, 430 mutations within the BRAF gene have been identified. The most common mutation is V600E. Here, thymine is substituted with adenine at nucleotide 1799. This causes a replacement of valine (V) by glutamate (E) at codon 600. Another important mutation described in MM is V600K. This mutation results in an amino-acid substitution at position 600 from a valine (V) to a lysine (K).
Different predictive assays are available and the different methods can be selected individually. But the predictive assay to be run by molecular pathology labs should detect the BRAF V600E mutation as well as the BRAF V600K mutation. In our material, the BRAF V600K mutation counts for ca 8-10% of the cases and cannot be neglected.
Decision on malignancy Another possible adjunct to diagnosis is testing for mutations to increase the confidence level when diagnosing a malignant disease of uncertain histogenesis. 54 This sometimes might be necessary since rendering a diagnosis of malignancy from small biopsies or cytological smears on morphological grounds alone might just not be possible with the necessary level of confidence, in particular when one considers all its far reaching consequences for the patient. In these instances, the detection of mutations known to be typical for the tumor in question might add an additional layer of security to the diagnostic procedure. This is true for the detection of BRAF V600E mutations in thyroid fine needle aspirates suspicious for papillary carcinoma or for the detection of KRAS mutations in small biopsies of the pancreas, which are suspicious for ductal adenocarcinoma. 55, 56 However, it must be noted that data on the frequency of mutations in benign mimickers of these diseases are sparse or controversial and therefore mutation analysis is only valid when properly interpreted in the context of the morphological findings.
Cancer of unknown primary/primary versus metastases Between 2 to 5% of all malignancies diagnosed in routine setting are classified as cancer of unknown primary. These patients are almost always treated with empiric chemotherapy, usually taxanes, platinum, gemcitabine or other conventional cytotoxic drugs. This is by far not the optimal treatment possible and the survival of these patients remains poor (medium OS ca 9 months). On the other hand, a definitive diagnosis could improve OS for months or if targeted drugs could be considered even longer. Thus, a reliable organ-specific histogenetic diagnosis is of utmost importance. In principle, there exist two approaches to optimize the diagnostic procedure, that is, as first step to investigate the tissue by a panel of IHC markers 57 and as second step to perform molecular tumor profiling. 58 In general, IHC is very helpful in developing the correct diagnoses, however, although there are at least 200 different antibodies, which can be used in routine diagnostics, the number of tumor-type or lineage-specific biomarker is limited. In this situation, molecular assays are helpful to achieve an accurate diagnosis. The reverse transcriptase-PCR-based 92-gene assay provided by bioTheranostics (San Diego, CA, USA) is currently the only assay, which has been proven to be relevant regarding clinical outcome. 59 The assay-directed treatment improves OS from 9 to 12 months.
In case a patient suffers from two or more tumors, the definition whether these are two or more primary tumors or metastatic lesions can be clinically relevant. The distinction becomes possible by differential screening of the whole genome. This can be done for example by using the comparative genomic hybridization. 60 Multi-gene assays (MGAs) of breast cancer to predict clinical outcome The purpose of MGA is directed to support clinicians and patients when a difficult decision has to be made. As an example, it is notoriously difficult to determine patients with Her2-negative and estrogen-receptor-positive breast cancer whether they need antihormone therapy only or whether additional chemotherapy is necessary for optimal results. This patient cohort cannot be reliably identified with conventional diagnostic methods. Traditionally, oncologists tend to (over)treat patients with chemotherapy only for security reasons although they would have been sufficiently treated with simple hormonal therapy alone.
The EndoPredict MGA is built on the quantitative analysis of 12 genes using real-time PCR. 61 The required starting material to run the assay is a single slice from FFPE tissue (needle biopsies or tumor blocks are equally sufficient. 62 The assay was trained on different cohorts of tumor patients encompassing nearly 1000 patients. All tumors used were ER þ /HER2-and treated only with endocrine therapy-accordingly, encompassing only patients from the medical relevant subgroup the EndoPredict is to be used for.
The EndoPredict was validated in two independent studies of the Austrian Breast and Colorectal Cancer Study Group. The results showed that the EndoPredict is able to identify a subgroup comprising roughly 60% of all patients of the two studies that have an average risk of recurrence of 4% over 10 years (Figure 4 ). This suggests that these patients can be safely spared from chemotherapy. It is important to note that the EndoPredict also operates in G2 tumors and in tumors classified as intermediate risk according to common treatment guidelines.
Comparing the diagnostic performance of the EndoPredict with the performance of the commonly used algorithms for patient stratification before breast cancer therapy it could be shown that the MGA adds statistically significant prognostic information to the currently used markers-no matter if alone or combined with each other. 61, 63 These RNA-based MGA are considered useful by international guidelines, like St Gallen or ASCO providing an additional possibility to solve the diagnostic dilemma described above. Goldhirsch et al. 64 stated 'Multigene assays are widely proposed to add to the prognostic information available from classical pathological markers and in some circumstances have been shown to identify groups which do or do not benefit from the addition of chemotherapy to endocrine adjuvant therapy'. Even the WHO stated in its 2012 blue book on breast cancer 65 'Probably the most promising and clinically useful area for the application of microarray analysis is the prediction of response to treatment, including chemotherapy, hormonal therapy, and radiation. y The prognostic gene-expression profiles that can be used in clinical practice y'.
The EndoPredict assay was performed in a decentralized manner in several institutes of pathology around Europe revealing high concordant result. 66 This gives predictive pathology the opportunity to perform the assay rapidly, close to the patients and the clinician's needs.
A similar assay particularly available in the United States is Oncotype DX provided by Genomic Health. Basically the results are similar, with some differences regarding an intermediate-risk group, the centralized doing and its unavailability in Europe.
Hematological tumors
Tumors of hematopoietic and lymphoid tissues frequently contain chromosomal translocations leading to the generation of novel fusion genes often exhibiting a tyrosine kinase activity. In addition single gene mutations appear to be important in the pathogenesis in various leukemias and lymphomas. Several of these genetic changes are or will become targets for a personalized therapy of these tumors.
BCR-ABL translocations. Chronic myeloid leukemia (CML), a myeloproliferative neoplasm, is caused by BCR-ABL1, a constitutively active fusion tyrosine kinase that is generated from the Philadelphia chromosome (Ph), the result of the translocation t(9;22)(q34;q11). 67 CML begins with a chronic phase characterized by the expansion of functionally normal myeloid lineage cells. Without effective therapy, there is progression to the blastic phase with CML progenitors losing terminal differentiation capacity. The unique presence of BCR-ABL1 in all CML cells and its absence from normal cells opened a therapeutic opportunity that became a reality with the discovery of Imatinib, a small molecule BCR-ABL1 tyrosine kinase inhibitor. 68 This has fundamentally improved CML prognosis, turning a fatal disease into a paradigm for molecular targeted therapy. The 5-year follow-up of newly diagnosed CML patients with chronic phase disease reported a cumulative complete cytogenetic response rate of 87% and projected overall and progression-free survival rates of 89% and 93%, respectively. 69 Conventional cytogenetic analysis remains the cornerstone for diagnosis and evaluation of therapy effect. A valid cytogenetic analysis requires evaluation of at least 20 metaphases of bone marrow cells. The molecular genetic analysis by means of real-time polymerase chain reaction allows quantification of the BCR-ABL1 transcript load and can therefore aid detection of molecular remission or of minimal residual disease.
Janus kinase 2 (JAK2) mutations. In Ph-negative myeloproliferative neoplasms the non-receptor tyrosine kinase JAK2 is frequently found to contain an activating V617F mutation. 70 This mutation is Predictive molecular pathology and its role in targeted cancer therapy M Dietel et al present at high frequency in patients with polycythemia vera, essential thrombocythemia and primary myelofibrosis. Signaling through the JAK2V617 mutation is thought to mediate hypersensitivity to growth factors as well as factor-independent growth, thus leading to aberrantly activating growth and survival pathways. The tremendous success of small-molecule tyrosine kinase inhibitors targeting BCR-ABL1 in CML has led to the development of related drugs that specifically inhibit kinases required for transformation in various malignancies. These drugs prevent interaction of ATP with its binding pocket in the catalytic site of the kinase. Currently, there are seven JAK2 kinase inhibitors in clinical trials. The JAK2 inhibitor Ruxolitinib was recently approved by the Food and Drug Administration for treatment of intermediate or high-risk myelofibrosis.
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BRAF mutations. BRAF, a serine-threonine protein kinase, is an essential component of the RAS-RAF-MEK-ERK signaling pathway, which is central in the regulation of cell proliferation and survival. This pathway is typically triggered by extracellular growth factors binding to receptor tyrosine kinases. BRAF is frequently mutated in various neoplasias (see above). The most common mutation is at position 600 of the BRAF protein, which becomes constitutively active independently of extracellular signals. Among myeloid neoplasms BRAF-V600E is frequently detected in Langerhans cell histiocytosis 72 and is the disease-defining genetic lesion in hairy cell leukemia (HCL). 73 The overwhelming majority of HCL cases examined until now show this mutation, which is not detectable in almost all investigated B-cell lymphoproliferative disorders. As a result of its specificity, the BRAF-V600E mutation provides a simple and very reliable genetic test for confirmation of HCL diagnosis, particularly in borderline or controversial cases. In addition, targeting the BRAF oncogene provides a new therapeutic opportunity for HCL, and the clinical efficacy of BRAF kinase inhibitors has been reported in single HCL cases.
ALK fusion genes. Another distinct target expressed in more than half of the cases of a particular peripheral T-cell lymphoma entity, the systemic ALCL, is the nucleophosmin (NPM)-ALK fusion protein. This fusion protein can be easily detected by immunohistochemistry. ALK is a receptor tyrosine kinase in the insulin receptor superfamily, and the NPM-ALK fusion protein is a result of chromosomal translocations between the ALK gene on chromosome 2 and the NPM gene on chromosome 5. Other fusions, such the EML4-ALK in NSCLC can also occur, but the NPM-ALK is the most common identified in ALCL. These fusions result in constitutive activation of ALK tyrosine kinase leading to the activation of multiple downstream pathways. Crizotinib is an inhibitor of ALK tyrosine kinase and successful treatment of ALK þ ALCL has been reported in pediatric patients and small case series, leading to ongoing trials in relapsed/refractory ALCL. 74 Diffuse large B-cell lymphoma (DLBCL) represents the most frequent type of malignant lymphoma. The cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapeutic regimen has been the standard care for DLBCL since several decades, producing cures only in about half of the patients. Additional application of the anti-CD20 antibody Rituximab has improved OS by another 10-15%. However, nearly 40% of the patients are refractory or relapse after initial therapy. Gene expression profiling has revealed two major molecular subtypes of DLBCL termed germinal center B-cell-like (GCB) DLBCL and activated B-cell like (ABC) DLBCL. Genome-wide profiling revealed that ABC-DLBCL preferentially present with and depend on activated nuclear factor-kB signaling, which is mainly driven by nuclear factor-kBactivating mutations in gene loci such as CARD11, A20, CD79-ITAM or My88. [74] [75] [76] Given the unsatisfying treatment results and the particularly poor outcome in ABC-DLBCL, there is urgent need to improve the current standard therapy for the entire DLBCL population or at least for a molecularly defined subset of patients that would selectively benefit from this novel therapeutic concept.
Mesenchymal tumors Molecular pathology testing as an adjunct to conventional tissuebased diagnosis of neoplastic diseases has evolved rapidly during the last 10 years. 77, 78 This development has been triggered by the finding that in hematologic, as well as in solid human tumors, preferably mesenchymal tumors, recurrent molecular aberrations can be found, which are fairly specific for certain subtypes of tumors. 79, 80 Examples for such molecular alterations are specific chromosomal translocations, which result in unique oncogenic fusion proteins. 81 This is a pathogenic mechanism, which can be observed in a large variety of mesenchymal (and hematological) neoplasm, which are sometimes hard to classify by morphological and immunohistochemical means alone. These translocations are used for diagnostic purposes. 82, 83 To do so, one can either entertain FISH with fusion probes or break apart probes or PCRbased methods with or without subsequent sequencing to detect fusion transcripts. Synovial sarcoma translocations. Within the heterogeneous group of human soft tissue tumors, particularly synovial sarcomas show a great spectrum of histological appearance and immunohistochemical reactions, which renders the reproducibility of the diagnoses a problem, even among experts. To get a clearer picture, it is mandatory to determine the translocation t (X;18), which is highly characteristic for this lesion. Another example is given in Figure 5 exemplifying the diagnosis of a Ewing sarcoma by a combined approach of immunohistochemical analysis and EWSR1 (22q12) dual-color, break-apart rearrangement probe FISH. There exist several techniques to do so, for example, chromogen in situ hybridization or FISH 'break apart probes'. Having the combination of characteristic histological and immunohistochemical features supplemented by typical genetic alterations the diagnosis can clearly be stated.
Central nervous system tumors Depending on certain cytological and histological criteria the WHO assigns four grades for CNS tumors (WHO grades I to IV). Although these grades are based on histopathological criteria characterizing malignancy, they also include and thus predict the expected clinical course of the patient. 84 Based on the rapid progress in the molecular understanding of the pathogenesis of brain tumors, in particular of glial tumors, new molecular signatures have been identified, which serve as reliable prognostic and predictive molecular markers. Based on several clinical studies three molecular markers-namely, 1p/19q co-deletion, MGMT promoter methylation and mutations in the IDH1/2 genes-just to mention the to date most prominent ones, have been identified to improve and manage patients' outcome.
Combined loss of 1p/19q in glial tumors. It has been shown that oligodendroglial tumors are characterized by combined allelic deletions on chromosome 1p and 19q. 85 Several clinical studies involving subjects suffering from anaplastic glioma demonstrated that only those patients benefit from radiotherapy, procarbazine, iomustin, vincristine chemotherapy or both that harbor a loss of 1p/19q. 86, 87 MGMT promoter methylation. The O 6 -methylguanine DNA methyltransferase (MGMT) is a DNA repair enzyme that removes the alkylation of the O 6 position of guanine, which protects DNA alkylation and finally apoptosis. Methylation of the MGMT promoter results in gene silencing because of reduced proficiency to repair DNA damage induced by alkylating chemotherapeutic agents like temozolomide. MGMT promoter methylation occurs in about 40% of primary glioblastoma (WHO grade IV) and is associated with an increased survival after radiotherapy and chemotherapy with temozolomide. 88, 89 Mutations of IDH1 and IDH2. Somatic point mutations of the IDH (isocitrate-dehydrogenase)1 and 2 genes are present in the vast majority of low-grade glioma, as well as in secondary glioblastoma. 90, 91 IDH1 and its mitochondrial isoform IDH2 encode for proteins, which catalyze isocitrate to a-ketoglutarate and have important roles in the cellular control of oxidative processes. In low-grade glioma subtypes and secondary glioblastoma, patients with IDH mutant tumors show longer OS than those with IDH wild-type neoplasms. Moreover, OS in patients with glioblastoma (WHO grade IV) with IDH1 mutation is longer than that of patients with anaplastic astrocytoma (WHO grade III) without IDH1 mutations. 92 The continuous identification of novel molecular signatures, apart from the above-mentioned ones, forces state-of-the-art neuropathology to broaden its diagnostic molecular spectrum by persistently implementing such molecular markers within the standard repertoire of diagnostic procedures used to characterize brain tumors.
The WHO-grading system of oligodendrogliomas is somewhat limited because of subjectivity of histopathological evaluation. Gene expression profiling now unraveled two molecularly distinct subgroups, which correspond to morphological grading and thus can be applied to provide a more objective tool for grading and prediction of prognosis. This approach may be extended toward other brain tumors where reproducible histological assessment often is difficult, if not impossible.
Perspectives on NGS
The upcoming technology of next-generation sequencing (NGS) has recently been adapted to diagnostic requirements. As even FFPE tissue can be used the procedures may be performed under routine conditions in near future. 93 The central aim of such analyses in cancer research will be the detection of drugable or actionable mutations to treat a patient with targeted drugs or combinations thereof according to the mutation pattern. In addition, improved sensitivity of NGS might enable non-invasive analyses such as early detection of relapse-determining mutations in blood or plasma samples from patients under treatment 94 and thus pave the way for a diagnostic cancer monitoring. Several platforms have been established recently for routine application providing highly sensitive analyses combined with acceptable costs and diagnostic real-time processing and data acquisition (for review, see Desai and Jere 95 ) . Among those are the Illumina MiSeq (Illumina, San Diego, CA, USA), the Roche 454 GS Junior (Roche, Basel, Switzerland) and the ABI IonTorrent Personal Genome Machine (PGM, Life Technologies Corporation, Carlsbad, CA, USA). The devices differ in technology and sample costs, as well as in sample throughput and are thus not equally well applicable for diagnostic applications. Using the IonTorrent PGM, Mellmann et al. 96 demonstrated NGS applicability and superiority by rapidly identifying the Escherichia coli strain causing the outbreak of the hemolytic uremic syndrome in Germany. Only recently, Marchetti et al. 97 re-evaluated lung cancer samples previously analyzed via Sanger Sequencing using the Roche 454 GS Junior NGS device and discovered a more complex pattern of EGFR deletions in exon 19 in a subset of patients. 97 These results show that NGS application is likely to outperform current diagnostic procedures and provide us with improved sensitivity and thus a broader molecular landscape of the samples under investigation. On comparison of IonTorrent-based NGS and Illumina exomeenriched NGS, we detected a high degree of accordance between the platforms also suggesting the requested reliability of this approach. A typical example is given in Figure 6 . CONCLUSIONS HER2/neu, BCR-ABL, EGFR, mutEGFR, KRAS wild type, mutBRAF, CD20, CD33, CD52, TOR and VEGF (just to name a few, see as well review Dietel and Sers 77 ) are specific goals for which targeted drugs have been developed, for example, trastuzumab (Herceptin), cetuximab (Erbitux), panitumumab (Vectibix), imatinib mesylate (Gleevec), bevacizumab (Avastin), Lapatinib, Bortezomib (Velcade), Gefitinib (Iressa), Erlotinib (Tarceva), Rituximab (MabThera), Alemtuzumab (Campath), Rapamycin (Rapamune) and many more. They are already used with considerable success in the clinic, however, to date the percentage of patients responding to the new inhibitors is often below 30%. This strongly indicates the need to improve the current portfolio of anticancer drugs.
The majority of the above mentioned drugs need a companion diagnostics to identify those patients who will benefit from the novel therapies. Special methods capable of detecting the entire spectrum of rate-limiting oncogenic pathways in tumors before and during therapy have been developed and adapted to routine diagnostic pathology. Clearly this will have an increasing role in the future tasks of pathological institutes and their diagnostic methods for routine work.
The developments described above will contribute to booster the possibilities to improve and stimulate molecular medicine. However, long-term benefits for patients concerning prolonged OS times or better therapy response could only be shown in a subgroup of patients. A major prerequisite is the interdisciplinary cooperation of basis scientists, clinically orientated physicians, diagnostic pathologists and clinicians, which all must speak the same 'language'. The 'translation' between different groups of researchers will be the challenging tasks in modern experimental and diagnostic pathology.
The implementation of bioinformatic procedures that will undergo further standardization together with highly parallel tissue analyses opens the door of improving the prediction the biological behavior of individual tumors. Such a 'multiplex approach' may help to functionally classify malignant tumors, assuming that a 'diagnostic algorithm', beginning with conventional histopathology in combination with immunohistochemistry provides the basis. This conventional morphological evaluation will then be supplemented by specialized disease-specific analyses such as different kinds of molecular assays, to predict tumorassociated features including tumor progression, drug response Figure 6 . An example of a rare malignant tumor, that is, a metastasized neuroendocrine carcinoma grade 3, with unknown druggable mutations. In a first approach, checking the current spectrum of mutation analyses by sequential standard procedures not one mutation was detected. Applying next-generation sequencing (IonAmpliseq, cancer panel in 46 gene) three druggable mutations could be discovered.
and metastatic potential, which all have an important impact on the adequate individual therapy.
These advances should have particular relevance for the development and clinical application of cancer gene therapies. A deeper understanding of the molecular pathways involved in cancer pathogenesis and treatment resistance will identify cancer gene therapy targets for gene replacement or suppression treatments. This knowledge will direct the construction of gene therapy vectors for particular molecular pathway abnormalities and guide their clinical development and future application in individual patients.
